Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors.
about
Plasma levels of soluble HLA-E and HLA-F at diagnosis may predict overall survival of neuroblastoma patientsChromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomasItalian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group.Update on pancreatic neuroendocrine tumors.Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors.Circulating Chromogranin A as A Marker for Monitoring Clinical Response in Advanced Gastroenteropancreatic Neuroendocrine TumorsPancreatic Neuroendocrine Tumors: an Update.Current concepts on gastric carcinoid tumors.Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learnedNovel autoantigens in type 1 diabetes.Advancements in pancreatic neuroendocrine tumors.Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan.Principles of diagnosis and management of neuroendocrine tumours.Chromogranin As a Biochemical Marker of Neuroendocrine Tumors.Analysis of 100 consecutive cases of resectable pancreatic neuroendocrine neoplasms: clinicopathological characteristics and long-term outcomes.Serum pancreastatin: the next predictive neuroendocrine tumor marker.Diagnosis of Pancreatic Neuroendocrine Tumors.Combined test of serum CgA and NSE improved the power of prognosis prediction of NF-pNETs.Somatostatin Analogs and Tumor Localization Do Not Influence Vitamin D Concentration in Patients with Neuroendocrine Tumors.Management and outcome of children with neuroendocrine tumors of the appendix in Spain: Is there room for improvement?Prognostic value of chromogranin A in patients with GET/NEN in the pancreas and the small intestine.
P2860
Q28304289-AF900E42-7D09-46A8-AE17-7A61F7BBA06FQ34036884-89E72DFF-754D-40A0-B4CA-A81CE981ABA6Q34157385-9B24AE62-F285-4361-9C96-92BC248BEDA6Q34446086-6D92500B-19FF-48CB-9845-86D8A1EEAF3FQ34453043-47B9EE25-2086-448C-8E38-1118E431167EQ35713515-717090BB-DB5E-4DCF-BB9C-2C5852FB515CQ36012272-C8548BA5-55BA-46B1-ADB3-200337CFCA57Q36400062-B99341E1-0AE7-4287-A267-346A89E52E20Q36499917-896DAF55-9453-48E0-BF19-4D673E7F6D26Q36871673-51968307-B8D9-4DC1-BBAE-C1FB0874E646Q36881807-8A6D4BC4-A4FA-4EC8-BF3F-FE2A3B5381F3Q38125257-7EE9CC31-80AA-4903-9E24-5DD53C0085D5Q38931272-C3D7A88C-EE78-4F5B-B7C2-BA80A1F77851Q39225250-9FECDE63-AB4C-4167-B358-DD4DE521D5E2Q39884069-FFB56304-5546-46D4-AB7F-CBDFC8AAA643Q40531429-2F240931-B742-4144-AEDD-6D73C6D95BB3Q44969569-4244C675-D6DF-4CC6-9AD6-062C0CAE34B3Q47165320-22BE3579-9AF6-4328-9C44-9C1BD149734AQ49165800-A9FDF248-82FE-49B2-A360-D0C7BF84CA48Q53133950-5426403F-63BF-4E04-8CC9-22B348A1D898Q53394010-E6C58CE6-06C8-4BAC-9299-407F7A096E65Q55263815-13BF6B05-0808-43F4-A7D7-03A6282BD8A9
P2860
Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Chromogranin A: a sensitive bi ...... creatic neuroendocrine tumors.
@en
type
label
Chromogranin A: a sensitive bi ...... creatic neuroendocrine tumors.
@en
prefLabel
Chromogranin A: a sensitive bi ...... creatic neuroendocrine tumors.
@en
P2860
P356
P1476
Chromogranin A: a sensitive bi ...... creatic neuroendocrine tumors.
@en
P2093
Calvin Law
Simron Singh
P2860
P304
P356
10.1586/EGH.12.15
P577
2012-06-01T00:00:00Z